All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Industry ReportApril 2026122,000+ words

The 2026 State of GLP-1 Telehealth

A data-driven analysis of 105 providers, pricing, patient safety, and regulatory compliance. The most detailed GLP-1 telehealth industry report ever published.

By FormBlends ResearchPublished April 9, 2026Last updated April 9, 2026

105

Providers Scored

16

Chapters

$100B+

Market Analyzed

85+

FDA Warnings Tracked

2026 GLP-1 telehealth report dashboard showing provider scores, pricing bands, FDA warnings, and patient review signals
The report analyzes provider scores, pricing bands, FDA warnings, review signals, and insurance access across the GLP-1 telehealth market.

Page refresh

2026 page notes for 2026 State of GLP-1 Telehealth Report

2026 State of GLP-1 Telehealth Report now adds practical 2026 context for GLP-1 telehealth provider rankings, 105 provider scores, pricing, FDA warnings, patient reviews, safety signals, compounded semaglutide, tirzepatide access, and provider comparison, and related searches such as 2026, state, glp-1, telehealth, report, provider, rankings, 105.

The details that matter here are the ones that change a real decision: what to verify, what can affect cost or safety, and how State Of Glp1 Telehealth 2026 compares with nearby GLP-1, peptide, provider, or treatment searches.

Before you act on this topic, check eligibility, clinician oversight, pharmacy sourcing, pricing, follow-up, side effects, and what a realistic result would look like for your situation.

2026 State of GLP-1 Telehealth Report GLP-1 telehealth provider rankings 2026 visual guide with 2026, state, glp-1, telehealth context

2026 State of GLP-1 Telehealth Report: custom 2026 visual context for GLP-1 telehealth provider rankings, 105 provider scores, pricing, FDA warnings, patient reviews, safety signals, compounded semaglutide, tirzepatide access, and provider comparison, and practical decision-making.

Image description: 2026 State of GLP-1 Telehealth Report custom image metadata for GLP-1 telehealth provider rankings, 105 provider scores, pricing, FDA warnings, patient reviews, safety signals, compounded semaglutide, tirzepatide access, and provider comparison, 2026, state, glp-1, telehealth, report, provider, rankings, 105, and FormBlends patient decision support.
Disclosure: FormBlends is both the publisher of this report and a GLP-1 provider scored within it. Our scoring methodology was applied equally to all providers, and our own weaknesses (no mobile app, newer brand, less funding) are documented honestly. This report contains no affiliate links. See Appendix G for our full conflict of interest statement.

Loading report (122,000+ words)...

Frequently Asked Questions

What is the best GLP-1 telehealth provider in 2026?
Based on our 100-point scoring of 105 providers, the top-rated platforms vary by category. For brand-name medications, Hims (72/100) and Found (69/100) lead. For compounded semaglutide with verified purity, FormBlends (78/100) and Eden (70/100) score highest. For full clinical programs, FORM Health (72/100) and Calibrate (62/100) offer the most structured approaches.
How much does GLP-1 medication really cost per month?
The true all-in cost averages $347/month for compounded semaglutide and $1,128/month for brand-name medications across 105 providers. Most advertised prices exclude membership fees, consultation charges, lab work, and dose escalation costs. The cheapest compounded options start around $119/month (Henry Meds) but carry regulatory and quality risks.
Which GLP-1 providers have received FDA warning letters?
The FDA issued 85+ warning letters to GLP-1 telehealth sellers between September 2025 and March 2026. Named recipients include Hims and Hers, MEDVi, Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx. Common violations include comparing compounded products to FDA-approved drugs and implying telehealth companies compound medications themselves.
Is compounded semaglutide safe?
Safety varies by source. Novo Nordisk testing found impurity levels up to 86% in some compounded injectable semaglutide and 75% in oral forms. Providers using NABP/PCAB-accredited pharmacies with published third-party Certificates of Analysis (COAs) on every batch offer better quality assurance. The FDA has cracked down on compounders since removing semaglutide from the shortage list in February 2025.
What is the difference between compounded and brand-name GLP-1 medications?
Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro) are FDA-approved with clinical trial data and standardized manufacturing. Compounded versions are mixed by pharmacies using the same active ingredient but without FDA approval for the final product. Compounded medications cost $99-299/month vs $149-599/month for brand-name. The FDA has issued 85+ warning letters to compounded GLP-1 sellers.
Which GLP-1 providers have mobile apps?
Only about 40% of GLP-1 telehealth providers offer dedicated mobile apps. Noom leads with a 4.7/5-rated app featuring AI Face Scan and behavior change curriculum. Hims, Ro, WeightWatchers, Found, and Mochi also have apps. Most compounding-focused providers including FormBlends, Eden, MEDVi, Henry Meds, and ShedRx operate web-only without mobile apps.
Does insurance cover GLP-1 medications for weight loss?
Only 19% of large employer health plans covered GLP-1s for weight loss as of January 2026. Medicare Part D coverage begins January 2027, with an early access GLP-1 Bridge program starting July 2026. Zepbound has a Medicare cap of $50/month starting April 2026. Providers like Found, WeightWatchers Clinic, and PlushCare offer the strongest insurance integration.
How many GLP-1 telehealth providers are there in the US?
We identified and scored 105 telehealth providers offering GLP-1 medications for weight loss in the United States as of April 2026. These range from publicly traded platforms like Hims ($2.35B revenue) and Ro ($7B valuation) to single-provider operations. We expect consolidation to reduce this to 30-40 viable operators by 2028.

Related on FormBlends

Provider Directory

7,282 GLP-1 provider profiles

Clinical Research

100+ peer-reviewed reports

Provider Comparisons

Side-by-side matchups

FormBlends vs Hims

Head-to-head analysis

FormBlends vs Ro

Head-to-head analysis

FormBlends vs Noom

Head-to-head analysis

FormBlends Products

Compounded semaglutide with COAs

Provider Finder Quiz

Find your best match

Not sure which provider is right for you?

Take our 2-minute quiz to get a personalized recommendation based on your budget, insurance, and treatment preferences.

Take the Quiz